Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria

Table 3 Difference in Progression-Free Survival (PFS) according to Response Criteria

Response Criteria	Median PFS, Months	95% CI	P-value for PFS Differences
Response Criteria	Median PFS, Months	95% CI	mRECIST	RANO-BM	iRANO-BM
mRECIST	7.73	4.52–18.05		0.031	0.001
RANO-BM	9.53	5.53–18.55	0.031		0.031
iRANO-BM	13.7	7.49–19.07	0.001	0.031

Calculated P-values (Wilcoxon signed rank test) for differences in PFS between assessment criteria are corrected for multiple comparisons (Bonferroni’s adjustment), and a P-value < 0.017 is considered significant. PFS, progression-free survival; CI, confidence interval

ISSN: 1470-7330